Randomized induction and post induction therapy in adult patients (= 1.5.
Completed
- Conditions
- Acute myelocytic leukemia, RAEB, RAEB-t.
- Registration Number
- NL-OMON25506
- Lead Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl
- Brief Summary
J Clin Oncol. 2007 Jan 1;25(1):1-2. Epub 2006 Dec 4.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 800
Inclusion Criteria
1. Age 18-60 years (incl.);
2. Subjects with a cytopathologically.
Exclusion Criteria
1. Prior chemotherapy within 6 months of study entry;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Endpoint for the comparison of induction treatment arm B with arm A and for the comparison yes or no G-CSF priming:<br /><br>1. Event-free survival (i.e., time from registration to induction failure, death or relapse whichever occurs first); the time to failure of patients with induction failure is set at one day.<br /><br><br /><br /><br>Endpoint for the comparison of PBSCT with cycle III:<br /><br>1. Disease-free survival measured from the date of second randomization to relapse or death from any cause.<br /><br><br /><br /><br>Endpoint for the evaluation of Allo SCT:<br /><br>1. Disease-free survival measured from the date of Allo SCT to relapse or death from any cause.
- Secondary Outcome Measures
Name Time Method